Abstract: Methotrexate has immunosuppressive effects and is administered for refractory chronic urticaria. We present a case of Pneumocystis jirovecii pneumonia in a patient with refractory chronic urticaria managed by low-dose weekly methotrexate treatment (total cumulative dose 195mg). Our study highlights the importance of providing prompt diagnosis and treatment of Pneumocystis jirovecii pneumonia in patients with chronic urticaria under methotrexate therapy.
INTRODUCTION
Chronic urticaria, characterized by continuous or intermittent urticarial eruption of wheals or hives for more than six weeks, has a ~0.5% to 1% lifetime prevalence in the general population. [1] [2] Antihistamines are the mainstay treatment and can control chronic urticaria in the majority of patients. Methotrexate (MTX) is an alternative agent with immunomodulatory effects that is employed in refractory chronic urticaria. However, the adverse effects or complications of MTX therapy in patients with chronic urticaria are scarcely reported. We present a rare case of Pneumocystis jirovecii pneumonia in a patient with refractory chronic urticaria receiving weekly MTX treatment. Our report highlights the importance of providing prompt diagnosis and treatment of Pneumocystis pneumonia in chronic urticaria patients receiving MTX therapy.
CASE REPORT
The patient, a 42-year-old woman, presented to our emergency department with a two-week history of dry cough, a oneweek history of progressive dyspnea and chest distress when taking a deep breath, and a four-day history of fever. She had an outpatient medical visit three days prior to presentation without symptom improvement. Of significance was her three-year history of chronic spontaneous urticaria on the face and forehead, which was initially controlled with first or second generation antihistamine agents.
This was not associated with autoimmunity, as there was no evidence of functional autoantibodies or other clinical manifestations.
However, prednisolone (10-30g/day) had been added during the previous year due to disease progression; MTX with folic acid supplementation had been employed during the previous three months as follows: 7.5mg/week for two weeks, 10mg/week for six weeks, and 15 mg/week for eight weeks (total dose, 195mg). In addition, the patient had a history of allergic rhinitis and bronchial asthma.
On examination, temperature was 38. Pneumocystis jirovecii pneumonia. 8 The typical chest radiography feature of Pneumocystis jirovecii pneumonia is bilateral reticular interstitial pattern with perihilar distribution. However, ~10% to 15% of patients who acquire
Pneumocystis jirovecii pneumonia have normal chest radiographic findings. 9 High-resolution computed tomography, which is more sensitive than chest radiography, is a good diagnostic tool in patients with a typical presentation of Pneumocystis jirovecii pneumonia such as progressive dyspnea, nonproductive cough, and lowgrade fever but normal chest radiographic findings. 
